💉 Winner in sight for RSV race; AstraZeneca dumps $855 million rare disease drug; Eli Lilly sees success in obesity drug trial

#329 | Oceans get hotter; Big Pharma’s R&D pipeline gets lighter; Mammalian genomes remain unchanged

and

Apr 28, 2023

∙ Paid

Hello, and welcome to the final Kable of a busy week and an even busier month. On this last day in April, life sciences news shows no signs of slowing down. Big Pharma is going full steam ahead with its restructuring plans, with companies streamlining their efforts by dumping some R&D projects and investing in more commercially-viable ones. Today’s Kabl…

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.